Skip to main content
. 2019 Nov 1;18(6):6423–6430. doi: 10.3892/ol.2019.11037

Table I.

Clinical characteristics of patients with spontaneously ruptured hepatocellular carcinoma.

Variable TACE cases, n (%) Surgery cases, n (%) P-value Total cases, n (%)
Age >60 years 13 (33.3) 7 (22.6) 0.323 20 (28.6)
Hypertension history 16 (41.0) 12 (38.7) 0.844 28 (40.0)
Child-Pugh <0.001
  A 11 (28.2) 29 (93.5) 40 (57.1)
  B 21 (53.8) 1 (3.2) 22 (31.4)
  C 7 (18) 1 (3.2) 8 (11.4)
AFP >400 ng/l 27 (69.2) 10 (32.3) 0.002 37 (52.9)
ALT >3 N 7 (17.9) 0 (0.0) 0.015 7 (9.9)
AST >3 N 17 (43.6) 6 (19.4) 0.032 23 (32.9)
TBIL >1.5 N 11 (28.2) 3 (9.7) 0.104 14 (20.0)
ALB ≤35 g/l 17 (43.6) 7 (22.6) 0.066 24 (34.3)
PT >16 sec 4 (10.2) 1 (3.2) 0.505 5 (7.1)
Hb, g/l <0.001
  >90 13 (33.3) 25 (80.6) 36 (51.4)
  90-60 23 (59.0) 6 (19.4) 29 (41.4)
  <60 3 (7.7) 0 (0.0) 3 (4.3)
Scr >1.5 N 2 (5.1) 0 (0.0) 0.499 2 (2.9)
Positive HBsAg status 35 (89.7) 17 (54.8) 0.002 52 (74.3)
Maximum tumor size, cm 0.655
  ≥5 9 (23.1) 8 (25.8) 17 (24.3)
  >5 and ≤10 18 (46.2) 11 (35.5) 29 (41.4)
  >10 12 (30.7) 12 (38.7) 24 (34.3)
Tumor number 0.037
  Single 18 (46.2) 22 (70.9) 40 (57.1)
  Multiple 21 (53.8) 9 (29.0) 30 (42.9)
Capsule formation 0.208
  Yes 18 (46.2) 19 (61.3) 37 (52.9)
  No 21 (53.8) 12 (38.7) 33 (47.1)
Vascular thrombus 0.391
  Yes 11 (28.2) 6 (19.4) 17 (24.3)
  No 28 (71.8) 25 (80.6) 53 (75.7)
Extrahepatic invasion
Yes 8 (20.5) 0 (0.0) 8 (11.4)
No 31 (79.5) 31 (100) 0.007 62 (88.6)
Shock 5 (12.8) 0 0.062 5 (7.1)
BCLC stage 0.049
  A 0 (0.0) 1 (3.2) 1 (1.4)
  B 22 (56.4) 24 (77.4) 46 (65.7)
  C 17 (43.6) 6 (19.4) 23 (32.9)
Hospital admission >10 days 9 (23.1) 19 (61.3) <0.001 28 (40.0)

TACE, transarterial chemoembolization; AFP, α-fetoprotein; N, normal level; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; PT, prothrombin time; Scr, serum creatinine; HbsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer.